Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Timil H. Patel
Observed name:
Timil Patel
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
ORCID:
0000-0003-2875-7761
Observed ORCID:
0000-0003-2875-7761
OpenAlex ID:
A5041174182
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
2023
·
Timil H. Patel
, Jamie R. Brewer
, et al.
·
Clinical Cancer Research
·
81
PDF
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement
2022
·
Timil H. Patel
, Leigh Marcus
, et al.
·
Clinical Cancer Research
·
76
PDF
Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19
2025
·
Timil H. Patel
, Amy Corneli
, et al.
·
Clinical Cancer Research
·
10
Adoption of decentralized trial elements in cancer clinical trials supporting FDA approvals during COVID-19.
2024
·
Timil Patel
, Amy Corneli
, et al.
·
Journal of Clinical Oncology
·
1
Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19
2025
·
Timil H. Patel
, Amy Corneli
, et al.
Supplementary Data from Adoption of Decentralized Trial Elements in Cancer Clinical Trials Supporting FDA Approvals during COVID-19
2025
·
Timil H. Patel
, Amy Corneli
, et al.
Reflections and Roadmaps: Career Development beyond the FDA-AACR Oncology Educational Fellowship
2024
·
Timil Patel
, Chris Chen
, et al.
·
Clinical Cancer Research
PDF
Show more works
View as search
Works count:
7
Citation count:
168
H-index:
3
I10-index:
3
Year
Topic
Type